P691 Cx601, a novel stem cell therapy for complex perianal fistulas in Crohn’s disease has rapid onset of clinical remission and low relapse rate by week 52

Individualised Care for Crohn’s Disease: Evolving Approaches for a Progressive Disease

“…Control that darvadstrocel treatment also resulted in more rapid healing than the current standard of care. 53 Relapse rates at Week 52 were lower with darvadstrocel compared with placebo (25.0% versus 44.1% [95% confidence interval: -39.5-1.3]), 53 which is particularly encouraging given that approximately half of patients treated with antiTNF therapy for perianal fistulas experience a recurrence. 54 The safety data at Week 52 confirmed a favourable tolerability profile for darvadstrocel, which was maintained over a prolonged period and the frequency and type of AE was similar in the two groups.…”